

### 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# **Prolia**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, druger)  Patient Name:		Prescriber Name:	The review process.	
Member Number:		Fax: Phone:		
Date of Birth:		Office Contact:		
Line of Business:   Exchange -	PA	NPI:	State Lic ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name (if ap	oplicable):	
☐ REQUEST FOR EXPEDITED REVIEW: Be the enrollee or the enrollee's ability to reg		I certify that the standard review timefr	rame may seriously jeopardize the life or health o	
Drug Name:				
Strength:				
Directions / SIG:				
Please attach any pertinen	· · · · · · · · · · · · · · · · · · ·	bs and information for this me ollowing questions and sign.	mber that may support approval.	
Q1. Request Type:				
☐ Initial - Go to 2		☐ Continuation - G	o to 12	
Q2. Diagnosis:				
☐ Postmenopausal ost	teoporosis - Go to 3			
☐ Osteoporosis in men - Go to 5				
☐ Glucocorticoid-induced osteoporosis - Go to 7				
<del>-</del>				
☐ Breast cancer - Go to 10 ☐ Prostate cancer - Go to 11				
☐ Prostate cancer - Go	וטוט			
Q3. Does the patient ha medical records.	ve a history of fragility	ractures? Attach support	ing chart notes or	
☐ Yes		□ No		
Q4. Does the patient have a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability and meets ANY of the following criteria:				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



### 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# **Prolia**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:		
A) Patient has indicators of very high fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [less than or equal to -3], or increased fall risk) B) Patient has failed prior treatment with or is intolerant to previous injectable osteoporosis therapy (e.g., zoledronic acid [Reclast], teriparatide [Forteo, Bonsity], abaloparatide [Tymlos]) C) Patient has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate? Must attach supporting chart notes or medical records.			
☐ Yes	□ No		
Q5. Does the patient have a history of an osteoporotic vertebral or hip fracture fractures (supporting chart notes or medical records attached)?			
☐ Yes	□ No		
Q6. Does the patient meets BOTH of the following criteria:  A) Patient has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability  B) Patient has had an oral OR injectable bisphosphonate trial of at least 1-year duration OR there is a clinical reason to avoid treatment with a bisphosphonate?  Must attach supporting chart notes or medical records.			
☐ Yes	□ No		
Q7. Is the patient currently receiving or will be initiating glucocorticoid therapy at an equivalent prednisone dose of greater than or equal to 2.5 mg/day for greater than or equal to 3 months?			
Q8. Has the patient had an oral OR injectable bisphosphonate trial of at least 1-year duration OR there is a clinical reason to avoid treatment with a bisphosphonate?			
☐ Yes	□ No		
Q9. Does the patient meet ANY of the following criteria: A) Patient has a history of a fragility fracture B) Patient has a pre-treatment T-score less than or equal to -2.5			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



### 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

# **Prolia**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
C) Patient has osteopenia (i.e., pre-treatment T-high pre-treatment FRAX fracture probability?  Must attach supporting chart notes or medical re		
☐ Yes	□ No	
Q10. Is the patient receiving adjuvant aromatase	inhibition therapy for breast cancer?	
□Yes	□ No	
Q11. Is the patient receiving androgen deprivation	on therapy for prostate cancer?	
☐ Yes	□ No	
Q12. Has the patient received less than 24 mont benefit (e.g., no new fracture seen on radiograph adverse events during therapy?	• • • • • • • • • • • • • • • • • • • •	
□Yes	□ No	
Q13. Has the patient experienced clinical benefit showing an improvement or stabilization in T-scome measurement and member has not experienced	ore compared with the previous bone mass	
☐ Yes	□ No	
Q14. Additional Information:		
Prescriber Signature	Date	
	2024 Prior Authorization Request	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document